FTO, as an oncogenic protein, participates in promoting AML cell proliferation and transformation while hindering AML cell differentiation and apoptosis, especially in AML subtypes with MLL-rearrangements and PML-RARA, FLT3-ITD and NPM1 mutations. The gene discussed is PML; the disease is acute myeloid leukemia.